Regulation of human IL12/IL23 responsiveness by IL12RB1
IL12RB1 对人类 IL12/IL23 反应性的调节
基本信息
- 批准号:9761425
- 负责人:
- 金额:$ 37.99万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2016
- 资助国家:美国
- 起止时间:2016-05-25 至 2021-04-30
- 项目状态:已结题
- 来源:
- 关键词:AIDS/HIV problemAffinityAlternative SplicingAntibiotic TherapyAutoimmunityBacteriaBindingBiochemicalBiological AssayCause of DeathCell Differentiation processCell NucleusCell surfaceCellsChemosensitizationComplexCytokine ReceptorsDataDiseaseDisulfidesDominant-Negative MutationEnvironmentExtracellular SpaceGenesGenetic Complementation TestGenetic TranscriptionHumanIL12RB1 geneImmune responseImmunobiologyImmunologicsImmunologyInterleukin-12KnowledgeLinkLungMalignant NeoplasmsMessenger RNAMethodsModelingMolecular BiologyMolecular ChaperonesMusMycobacterium tuberculosisNeutrophil InfiltrationPatientsPeripheral Blood Mononuclear CellPhosphorylationProductivityPropertyProtein IsoformsProteinsReagentReceptor SignalingRecurrenceRegulationReporterResearchResearch PersonnelResearch Project GrantsResistanceSignal PathwaySignal TransductionSiteSurfaceT cell responseT-LymphocyteTestingTranslatingTuberculosisbasecytokineextracellularhuman diseasehuman modelin vivoinnovationinterleukin-23macrophagenovelpathogenic bacteriareceptorresponsetransmission processtuberculosis treatment
项目摘要
ABSTRACT
Tuberculosis (TB) is a human disease caused by the bacterial pathogen Mycobacterium tuberculosis (Mtb). In
2015, TB ranked above HIV/AIDs as a leading cause of death worldwide. The gene IL12RB1 regulates human
resistance to TB by promoting cytokine (IL12/IL23)-dependent differentiation of naïve TH cells into TH1 and
TH17 effectors. TH1 and TH17 cells limit Mtb survival by activating Mtb-infected macrophages and recruiting
neutrophils to infected sites. It was established >20 years ago that IL12RB1 is transcribed and translated into
IL12Rβ1, a transmembrane receptor on the TH cell surface that binds IL12/IL23, and then complexes with
secondary receptors (IL12Rβ2, IL23R) to activate the intracellular signaling cascades that drive TH1/TH17
differentiation. However, we recently demonstrated that IL12RB1 is also transcribed and translated into a
second isoform (Isoform 2, or Iso2) that is a secreted potentiator of IL12/IL23 activity. The mechanism whereby
Iso2 potentiates IL12/IL23 activity is not known. Here, we propose a research project that will both fill important
gaps in our knowledge of IL12RB1 and determine the mechanism of Iso2 potentiation. This project is
significant since IL12RB1 regulates multiple immune responses including TB-resistance, and innovative
since it will establish a paradigm for how natural soluble cytokine receptors potentiate cytokine activity. This
project is also being pursued by an investigator with demonstrated independent expertise and productivity in
the field of IL12RB1-TB interactions, in an environment that is highly supportive of basic immunology
research. Finally, the methods and approach we use build on our demonstrated expertise in molecular
biology, immunology and the mouse TB model. There are two Specific Aims: (AIM 1) Determine the
biochemical mechanism that Isoform 2 enhances IL12/IL23 signaling; (AIM 2) Determine the immunological
mechanism that Isoform 2 increases TB resistance. At the end of our studies, we will have extended our basic
understanding of IL12RB1 immunobiology in the context of TB, as well as generated novel proteins with
potential use as an adjunct TB therapy. Since IL12RB1's influence extends beyond TB to also include
autoimmunity, cancer, and atopic disease, the mechanisms we identify are relevant to these other human
diseases.
摘要
结核病(TB)是由细菌病原体结核分枝杆菌(Mtb)引起的人类疾病。在
2015年,结核病超过艾滋病毒/艾滋病,成为全球主要死亡原因。IL 12 RB 1基因调控人类
- 通过促进细胞因子(IL 12/IL 23)依赖性的幼稚TH细胞分化为TH 1和
TH 17效应器。TH 1和TH 17细胞通过激活Mtb感染的巨噬细胞和募集来限制Mtb的存活
中性粒细胞感染部位。20年前就已经确定,IL 12 RB 1转录并翻译成
IL 12 R β1,TH细胞表面上的跨膜受体,其结合IL 12/IL 23,然后与
次级受体(IL 12 R β2、IL 23 R),以激活驱动TH 1/TH 17的细胞内信号级联
分化然而,我们最近证明,IL 12 RB 1也被转录和翻译成一种蛋白质。
第二同种型(同种型2,或Iso 2),其是IL 12/IL 23活性的分泌增强剂。的机理
Iso 2增强IL 12/IL 23活性尚不清楚。在这里,我们提出了一个研究项目,既将填补重要的
我们对IL 12 RB 1的认识中的空白,并确定Iso 2增强的机制。这个项目是
由于IL 12 RB 1调节包括TB抗性在内的多种免疫应答,
因为它将建立天然可溶性细胞因子受体如何增强细胞因子活性的范例。这
一名调查员也在进行该项目,该调查员在以下方面具有独立的专门知识和生产力:
IL 12 RB 1-TB相互作用领域,在高度支持基础免疫学的环境中
research.最后,我们使用的方法和途径建立在我们在分子生物学领域的专业知识基础上。
生物学、免疫学和小鼠结核病模型。有两个具体目标:(目标1)确定
同种型2增强IL 12/IL 23信号传导的生化机制;(AIM 2)确定免疫学
同种型2增加TB抗性的机制。在我们的研究结束时,我们将扩大我们的基本
在结核病背景下对IL 12 RB 1免疫生物学的理解,以及产生具有
作为结核病辅助治疗的潜在用途。由于IL 12 RB 1的影响超出了结核病,
自身免疫,癌症和特应性疾病,我们确定的机制与这些其他人类疾病有关。
疾病
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Richard Robinson其他文献
Richard Robinson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Richard Robinson', 18)}}的其他基金
Regulation of human IL12/IL23 responsiveness by IL12RB1
IL12RB1 对人类 IL12/IL23 反应性的调节
- 批准号:
9751475 - 财政年份:2016
- 资助金额:
$ 37.99万 - 项目类别:
Regulation of human IL12/IL23 responsiveness by IL12RB1
IL12RB1 对人类 IL12/IL23 反应性的调节
- 批准号:
9925176 - 财政年份:2016
- 资助金额:
$ 37.99万 - 项目类别:
Neuronal and Developmental Regulation of Pacemaker Channels
起搏器通道的神经元和发育调节
- 批准号:
6740406 - 财政年份:2003
- 资助金额:
$ 37.99万 - 项目类别:
相似海外基金
Construction of affinity sensors using high-speed oscillation of nanomaterials
利用纳米材料高速振荡构建亲和传感器
- 批准号:
23H01982 - 财政年份:2023
- 资助金额:
$ 37.99万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Affinity evaluation for development of polymer nanocomposites with high thermal conductivity and interfacial molecular design
高导热率聚合物纳米复合材料开发和界面分子设计的亲和力评估
- 批准号:
23KJ0116 - 财政年份:2023
- 资助金额:
$ 37.99万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Development of High-Affinity and Selective Ligands as a Pharmacological Tool for the Dopamine D4 Receptor (D4R) Subtype Variants
开发高亲和力和选择性配体作为多巴胺 D4 受体 (D4R) 亚型变体的药理学工具
- 批准号:
10682794 - 财政年份:2023
- 资助金额:
$ 37.99万 - 项目类别:
Platform for the High Throughput Generation and Validation of Affinity Reagents
用于高通量生成和亲和试剂验证的平台
- 批准号:
10598276 - 财政年份:2023
- 资助金额:
$ 37.99万 - 项目类别:
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233343 - 财政年份:2023
- 资助金额:
$ 37.99万 - 项目类别:
Standard Grant
Collaborative Research: DESIGN: Co-creation of affinity groups to facilitate diverse & inclusive ornithological societies
合作研究:设计:共同创建亲和团体以促进多元化
- 批准号:
2233342 - 财政年份:2023
- 资助金额:
$ 37.99万 - 项目类别:
Standard Grant
Molecular mechanisms underlying high-affinity and isotype switched antibody responses
高亲和力和同种型转换抗体反应的分子机制
- 批准号:
479363 - 财政年份:2023
- 资助金额:
$ 37.99万 - 项目类别:
Operating Grants
Deconstructed T cell antigen recognition: Separation of affinity from bond lifetime
解构 T 细胞抗原识别:亲和力与键寿命的分离
- 批准号:
10681989 - 财政年份:2023
- 资助金额:
$ 37.99万 - 项目类别:
CAREER: Engineered Affinity-Based Biomaterials for Harnessing the Stem Cell Secretome
职业:基于亲和力的工程生物材料用于利用干细胞分泌组
- 批准号:
2237240 - 财政年份:2023
- 资助金额:
$ 37.99万 - 项目类别:
Continuing Grant
ADVANCE Partnership: Leveraging Intersectionality and Engineering Affinity groups in Industrial Engineering and Operations Research (LINEAGE)
ADVANCE 合作伙伴关系:利用工业工程和运筹学 (LINEAGE) 领域的交叉性和工程亲和力团体
- 批准号:
2305592 - 财政年份:2023
- 资助金额:
$ 37.99万 - 项目类别:
Continuing Grant














{{item.name}}会员




